SFDA Prepares to Revise Supervision Regulations for ADR     

China's State Food and Drug Administration (SFDA) released on November 6th that it is considering to revise the current supervision and management regulation on adverse drug reaction (ADR), which was issued in 2004.
   The current regulation requires the healthcare offices, the food and drug administrations, hospitals, drug producers and traders to report ADR as soon as it is found. In fact, however, less ADR reports came from drug producers or traders, around 10% only. In China drugs are often consumed through doctors, therefore patients are used to report ADR directly to their doctors. The releaser of SFDA commented that drug producers have responsibility to report ADR and modify production technology actively. SFDA hopes the proposed revision will encourage producers to report ADR.